Dopamine receptor-mediated regulation of corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus

Brain Research
M J EatonK J Lookingland

Abstract

The present study examined the effects of intraperitoneal administration of selective D1 (SKF 38393) and D2 (quinelorane) dopaminergic receptor agonists on Fos-like immunoreactivity (Fos-LI) and levels of corticotropin-releasing hormone (CRH) mRNA in the paraventricular nucleus of the hypothalamus (PVN) and in the central nucleus of the amygdala (cAMY). Ninety minutes after administration of the D1 agonist SKF 38393, Fos-LI was increased in both the PVN and cAMY. Administration of SCH 39166, a selective D1 antagonist, blocked and attenuated the SKF 38393-induced increase in Fos-LI in the PVN and cAMY, respectively. Similarly, 90 minutes after intraperitoneal injection of the D2 agonist quinelorane, Fos-LI was increased in both PVN and cAMY. Administration of the selective D2 antagonist raclopride prevented the ability of quinelorane to increase Fos-LI in the PVN and cAMY. Both SKF 38393 and quinelorane stimulated the expression of CRH and mRNA in the PVN, but failed to alter its expression in the cAMY. Taken together, these results indicate that stimulation of either D1 and D2 dopaminergic receptors activates CRH neurons in the PVN. Stimulation of either D1 or D2 receptors activates neurons in the cAMY, but these changes do not...Continue Reading

References

Feb 15, 1978·The Journal of Comparative Neurology·R Y Moore
May 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·R T FremeauM G Caron
Dec 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·W S YoungM R Brann
Aug 14, 1989·FEBS Letters·D M Weiner, M R Brann
Jan 1, 1994·Pharmacology & Therapeutics·D M Jackson, A Westlind-Danielsson

❮ Previous
Next ❯

Citations

Sep 22, 2001·Pharmacology, Biochemistry, and Behavior·C ArévaloR Hernández-Tristán
Mar 16, 2000·Journal of Neuroendocrinology·H KinoshitaM S Harbuz
Nov 24, 2011·Physiology & Behavior·Olivier GeorgeGeorge F Koob
Nov 5, 2004·The European Journal of Neuroscience·Christelle MonacaPhilippe Derambure
Sep 20, 2006·Progress in Neurobiology·Norman PecoraroSusan F Akana
Oct 26, 2013·Neuropharmacology·Celina Y MojicaFrances M Leslie
Oct 23, 2012·Neuroscience and Biobehavioral Reviews·Judith BuseVeit Roessner
May 1, 1997·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·P Fadda, W Fratta
Aug 22, 2001·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·E E HermelA B Lucion
Feb 12, 2014·Behavior Modification·Judith BuseVeit Roessner
Feb 17, 2018·Pharmaceutical Research·Willem Johan van den BrinkElizabeth Cunera Maria de Lange
Sep 20, 2008·Neuroscience and Behavioral Physiology·G A OganesyanI V Artamokhina
Jul 9, 2020·Journal of Clinical Psychopharmacology·Ludovic Christophe JeanjeanClément Gendrault
Oct 27, 2020·Frontiers in Psychiatry·Fabrice DuvalLudovic Jeanjean

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.